+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2026-2032- Product Image
Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2026-2032- Product Image
Sale

Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081575
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted PSMA Radionuclide Drug Conjugates Market is projected to reach USD 1.03 Billion in 2026. It is expected to continue growing at a CAGR of 11.62%, reaching USD 2.02 Billion by 2032.

Targeted PSMA Radionuclide Drug Conjugates: Executive Overview

Targeted PSMA radionuclide drug conjugates are an emerging precision-oncology approach that combines prostate-specific membrane antigen (PSMA) recognition with therapeutic radioisotopes. Their development is centered on improving selective radiation delivery to PSMA-expressing tumors while managing radiation exposure to normal tissues. Clinical adoption depends on evidence of benefit, patient selection, radiopharmaceutical manufacturing, specialized imaging and treatment infrastructure, and regulatory alignment.

Clinical Translation Is Reshaping PSMA-Directed Radiotherapy

The field is moving from proof-of-concept toward more integrated care pathways that connect PSMA imaging, treatment planning, dosimetry, administration, and follow-up. Important shifts include greater attention to earlier lines of therapy, combination regimens, resistance biology, renal and marrow safety, and consistent production of radiolabeled products. These changes are also increasing the importance of multidisciplinary teams involving nuclear medicine, medical oncology, radiation safety, pharmacy, radiochemistry, and medical physics.

Artificial Intelligence Strengthens Selection, Imaging, and Operational Control

Artificial intelligence can support PSMA image interpretation, lesion segmentation, response assessment, and identification of imaging patterns associated with treatment benefit or toxicity. In development and clinical operations, machine-learning tools may assist dosimetry, trial matching, workflow scheduling, isotope logistics, and quality assurance. Effective use requires representative datasets, external validation, explainable outputs, protection of patient data, and clinician oversight; AI should augment rather than replace multidisciplinary judgment.

Regional Priorities Differ by Infrastructure, Regulation, and Isotope Access

North America is characterized by advanced theranostic infrastructure, active clinical research, and established specialist networks, while Latin America faces wider variation in isotope supply, reimbursement, and access to nuclear medicine services. Europe benefits from sophisticated radiopharmacy and cross-border research capabilities, although national health-technology assessment and reimbursement processes differ. The Middle East is expanding specialized oncology and nuclear medicine capacity, whereas Africa remains highly heterogeneous, with access concentrated in better-resourced centers. Asia-Pacific combines strong capabilities in countries such as Japan, South Korea, Australia, and China with substantial differences in regulatory pathways, manufacturing capacity, and rural access across the region.

Economic and Security Groups Shape Collaborative Readiness

ASEAN markets are likely to benefit from regional cooperation in training, isotope logistics, and referral pathways, while BRICS members reflect diverse capabilities spanning research, manufacturing, and clinical delivery. European Union systems emphasize coordinated evidence generation alongside nationally managed access decisions. G7 countries generally have mature oncology and radiopharmacy ecosystems, but still face workforce and capacity constraints. GCC states are investing in advanced healthcare infrastructure and can serve as regional referral hubs. NATO members share extensive clinical and scientific networks, although readiness for radioligand delivery remains uneven across national health systems.

Country-Level Capacity Depends on Evidence, Workforce, and Supply Chains

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, the United States, Japan, South Korea, and China have notable capabilities in nuclear medicine, oncology research, or radiopharmaceutical development, though their approval, reimbursement, and service-delivery models differ. India, Brazil, Mexico, and Russia have substantial clinical and scientific potential but face varied constraints involving specialized workforce availability, isotope distribution, regional infrastructure, and affordability. Across all listed countries, sustainable deployment will depend on validated clinical evidence, reliable radiopharmaceutical production, radiation-safety systems, and equitable referral access.

Priorities for Leaders: Build Evidence and Delivery Capability Together

Industry leaders should align development programs with clinically meaningful endpoints, prospectively defined PSMA imaging criteria, and transparent safety monitoring. They should establish resilient isotope and radiopharmacy networks, invest in dosimetry and workforce training, and engage regulators and payers early. Partnerships with hospitals can help standardize patient selection and treatment workflows, while interoperable data systems can support real-world evidence. AI initiatives should begin with narrowly defined, clinically validated use cases and strong governance for bias, privacy, cybersecurity, and accountability.

Methodology: Structured Synthesis of the Targeted PSMA Therapy Landscape

This executive summary uses a qualitative synthesis framework focused on the scientific, clinical, operational, regulatory, and geographic dimensions of targeted PSMA radionuclide drug conjugates. The assessment organizes verified concepts around treatment mechanisms, patient-selection practices, care infrastructure, isotope and radiopharmacy requirements, artificial-intelligence applications, and access conditions across the specified regions, groups, and countries. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis.

Conclusion: Precision Delivery Requires an Integrated Health-System Model

Targeted PSMA radionuclide drug conjugates have strategic relevance because they connect molecular imaging, targeted radiation, and precision oncology within a single care pathway. Progress will depend not only on therapeutic efficacy, but also on safe isotope handling, reproducible manufacturing, skilled teams, validated diagnostics, and sustainable patient access. Leaders that coordinate clinical evidence, infrastructure, regulation, and responsible digital innovation will be best positioned to translate the modality’s potential into dependable patient care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Targeted PSMA Radionuclide Drug Conjugates Market, by Radionuclide Type
7.1. Introduction
7.2. Actinium-225
7.3. Gallium-68
7.4. Lutetium-177
7.5. Technetium-99m
8. Targeted PSMA Radionuclide Drug Conjugates Market, by Indication
8.1. Introduction
8.2. Metastatic Castration-Resistant Prostate Cancer
8.3. Metastatic Castration-Sensitive Prostate Cancer
8.4. Non-Metastatic Prostate Cancer
9. Targeted PSMA Radionuclide Drug Conjugates Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Targeted PSMA Radionuclide Drug Conjugates Market, by Patient Age Group
10.1. Introduction
10.2. Adult 18-65
10.3. Senior 65+
11. Targeted PSMA Radionuclide Drug Conjugates Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Hospital
11.4. Imaging Center
11.5. Research Institute
12. Targeted PSMA Radionuclide Drug Conjugates Market, by Distribution Channel
12.1. Introduction
12.2. Direct Purchase
12.3. Hospital Pharmacy
12.4. Specialty Pharmacy
13. Targeted PSMA Radionuclide Drug Conjugates Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Targeted PSMA Radionuclide Drug Conjugates Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Targeted PSMA Radionuclide Drug Conjugates Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Actinium Pharmaceuticals, Inc.
17.2. ACUITY Pharmaceuticals, Inc.
17.3. Advanced Accelerator Applications
17.4. Bayer AG
17.5. Curium Pharma S.A.
17.6. Endocyte Therapeutics GmbH
17.7. GE Healthcare Limited
17.8. Isoray Medical, Inc.
17.9. ITM Isotope Technologies Munich SE
17.10. Jubilant Life Sciences Limited
17.11. Lantheus Holdings, Inc.
17.12. Novartis AG
17.13. Point Biopharma Global Inc.
17.14. Point Biopharma Inc.
17.15. PSMA Therapeutics LLC
17.16. RadioMedix, Inc.
17.17. Sorrento Therapeutics, Inc.
17.18. Telix Pharmaceuticals Limited
17.19. Telix Pharmaceuticals Pty Ltd
17.20. Theragnostics, Inc.
17.21. Viamet Pharmaceuticals, Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Targeted PSMA Radionuclide Drug Conjugates Market, Years Considered for the Study
FIGURE 2. Global Targeted PSMA Radionuclide Drug Conjugates Market, Research Design
FIGURE 3. Global Targeted PSMA Radionuclide Drug Conjugates Market, Research Framework
FIGURE 4. Global Targeted PSMA Radionuclide Drug Conjugates Market, Data Triangulation
FIGURE 5. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2025 vs 2032 (%)
FIGURE 7. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 11. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Targeted PSMA Radionuclide Drug Conjugates Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Targeted PSMA Radionuclide Drug Conjugates Market Segmentation & Coverage
TABLE 2. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 3. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 4. Global Actinium-225 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Actinium-225 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Actinium-225 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gallium-68 Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gallium-68 Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gallium-68 Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lutetium-177 Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lutetium-177 Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lutetium-177 Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Technetium-99m Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Technetium-99m Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Technetium-99m Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Metastatic Castration-Sensitive Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Metastatic Castration-Sensitive Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Metastatic Castration-Sensitive Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Non-Metastatic Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Non-Metastatic Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Non-Metastatic Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 27. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 34. Global Adult 18-65 Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Adult 18-65 Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Adult 18-65 Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Senior 65+ Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Senior 65+ Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Senior 65+ Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 41. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Imaging Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Imaging Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Imaging Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Research Institute Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Research Institute Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Research Institute Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. Global Direct Purchase Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Direct Purchase Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Direct Purchase Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 71. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 73. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 74. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 75. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. North America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 80. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 82. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 83. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 87. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 89. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 90. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 94. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 95. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 96. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 97. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Middle East Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 101. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 102. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 103. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 104. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Africa Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 109. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 111. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 112. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. ASEAN Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 116. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 117. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 118. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. GCC Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 123. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 125. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 126. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. European Union Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 130. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 132. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. BRICS Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 137. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 138. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 140. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. G7 Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 144. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 146. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. NATO Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Global Targeted PSMA Radionuclide Drug Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 151. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 152. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 154. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 155. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. United States Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 158. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 159. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 161. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Canada Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 165. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 166. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 168. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 169. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 172. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 173. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 174. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 175. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 176. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 179. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 180. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 182. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 183. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 186. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 187. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 189. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Germany Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. France Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 193. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 194. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 196. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. France Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 200. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 201. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 203. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 204. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Russia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 207. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 208. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 209. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 210. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Italy Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 214. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 215. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 217. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 218. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Spain Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. China Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 221. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 222. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 223. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 224. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 225. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. China Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. India Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 228. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 229. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 230. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 231. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 232. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. India Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 235. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 236. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 238. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 239. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Japan Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 242. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 243. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 245. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. Australia Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, 2017-2032 (USD Million)
TABLE 249. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 250. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 252. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Global Targeted PSMA Radionuclide Drug Conjugates Market Share, by Key Player, 2025
TABLE 256. Global Targeted PSMA Radionuclide Drug Conjugates Market, Key Experts

Companies Mentioned

  • Actinium Pharmaceuticals, Inc.
  • ACUITY Pharmaceuticals, Inc.
  • Advanced Accelerator Applications
  • Bayer AG
  • Curium Pharma S.A.
  • Endocyte Therapeutics GmbH
  • GE Healthcare Limited
  • Isoray Medical, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Life Sciences Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Point Biopharma Global Inc.
  • Point Biopharma Inc.
  • PSMA Therapeutics LLC
  • RadioMedix, Inc.
  • Sorrento Therapeutics, Inc.
  • Telix Pharmaceuticals Limited
  • Telix Pharmaceuticals Pty Ltd
  • Theragnostics, Inc.
  • Viamet Pharmaceuticals, Inc.

Related Topics

Related Reports

Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 432 Pages
  • Global
From
Metastatic Prostate Cancer Market Report 2026 - Product Image

Metastatic Prostate Cancer Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032 - Product Image

Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Hormone Refractory Prostate Cancer Market Report 2026 - Product Image

Hormone Refractory Prostate Cancer Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Global Forecast 2026-2032 - Product Image

Prostate Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.